Last reviewed · How we verify
Ofloxacin 0.3%
Ofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.
Ofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription. Used for Bacterial conjunctivitis, Bacterial corneal ulcers, Ocular infections caused by susceptible gram-positive and gram-negative bacteria.
At a glance
| Generic name | Ofloxacin 0.3% |
|---|---|
| Sponsor | Indiana University School of Medicine |
| Drug class | Fluoroquinolone antibiotic |
| Target | DNA gyrase, Topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Ofloxacin works by binding to and inhibiting bacterial DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for DNA replication and repair. This leads to disruption of bacterial DNA synthesis, cell death, and bactericidal activity. The 0.3% ophthalmic formulation is used topically on the eye to treat bacterial infections.
Approved indications
- Bacterial conjunctivitis
- Bacterial corneal ulcers
- Ocular infections caused by susceptible gram-positive and gram-negative bacteria
Common side effects
- Ocular irritation
- Conjunctival hyperemia
- Photophobia
- Lid edema
Key clinical trials
- Does Topical Otic Drop Use at Time of Tympanostomy Tube Surgery Improve Outcomes When no Middle Ear Effusion is Present (PHASE4)
- Safety Profile of Applied 100% Manuka Honey in Tympanoplasty (PHASE2, PHASE3)
- Effects of 100% Medical Grade Manuka Honey on Tympanic Membrane Reconstruction Healing. (PHASE2, PHASE3)
- Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media (NA)
- Concentration of Ofloxacin Into the Aqueous Humour of Patients With Dry Eye Disease (PHASE4)
- Association Between SNP of SP-D and Susceptibility and Prognosis of Infectious Keratitis
- Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects (PHASE1)
- Early Changes Between Lenticule Extraction and Small-Incision Lenticule Extraction (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |